Physician profile
John D Strickley
NPI 1932637188
$4,016.26
in general payments reported to CMS, 2019-2025
26 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,401 · 2024: $1,234 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.13 |
| Education | $420.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.32 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $845.25 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $364.53 | 2023-2025 | |
| Lilly USA, LLC | $186.04 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $166.67 | 2023-2024 | Sotyktu |
| Ucb, INC. | $161.26 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $142.07 | 2024-2025 | Opzelura |
| Genzyme Corporation | $127.76 | 2023-2025 | |
| Kyowa Kirin, INC. | $119.70 | 2024 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $115.56 | 2023-2025 | Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.96 | 2023-2025 | Spevigo |
| Krystal Biotech INC | $100.86 | 2023 | Vyjuvek |
| Amgen INC. | $92.85 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $70.30 | 2023-2025 | Dupixent, Libtayo |
| Nobelpharma America, LLC | $65.80 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $51.86 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $36.89 | 2023-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $35.80 | 2023 | Ycanth |
| Sandoz INC. | $34.37 | 2023-2024 | Hyrimoz |
| Mayne Pharma Commercial LLC | $34.09 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.00 | 2024 | Cabtreo |
| Biofrontera INC. | $19.99 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $18.89 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $15.05 | 2024 | Nuzyra |
| Springworks Therapeutics, INC. | $14.22 | 2025 | Gomekli |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strickley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.